Response Genetics Cites Delay in Test Samples for Q4 Revenue Decline | GenomeWeb

NEW YORK (GenomeWeb News) – Response Genetics reported after the close of the market on Thursday that its fourth-quarter revenues fell 41 percent due primarily to a delay in receiving clinical samples from pharmaceutical customers.

The Los Angeles-based molecular diagnostics test developer and lab operator reported revenues of $1.4 million for the three-month period ended Dec. 31, compared to revenues of $2.4 million for the fourth quarter of 2007. The company said that it anticipates receiving those delayed clinical samples in 2009 through 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.